A prospectus supplement relating to the new Convertible Senior Notes to be issued in the offering has been filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119.
This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.
This press release contains forward-looking statements that involve a
number of risks and uncertainties, the outcome of which could materially
and/or adversely affect future results. The risks and uncertainties include
that the Company continues to have substantial amount of debt outstanding
and the quarterly interest expense associated with the debt is significant;
the Company's operating expenses continue to exceed its net revenues and
the Company will continue to need to raise capital to fund its operating
expenses; as well as other risks listed or described from time to time in
the Company's most recent filings with the SEC on Forms 10-K, 8-K and 10-Q.
Except as required by law, the Company does not intend to update any of the
statements in this press release upon further developments.
Lindsey Jesch Logan
T : 206.272.4347
F : 206.272.4434
|SOURCE Cell Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved